Teva Pharmaceutical Industries (TEVA) Panoramica del titolo
Teva Pharmaceutical Industries Limited sviluppa, produce, commercializza e distribuisce farmaci generici e di altro tipo e prodotti biofarmaceutici negli Stati Uniti, in Europa, in Israele e a livello internazionale. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 2/6 |
| Crescita futura | 4/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 2/6 |
| Dividendi | 0/6 |
Premi
Analisi del rischio
TEVA Community Fair Values
Create NarrativeSee what 104 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Teva Pharmaceutical Industries Limited
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$37.09 |
| Massimo di 52 settimane | US$38.37 |
| Minimo di 52 settimane | US$18.21 |
| Beta | 0.87 |
| Variazione di 1 mese | 0.95% |
| Variazione a 3 mesi | 7.10% |
| Variazione di 1 anno | 86.10% |
| Variazione a 3 anni | 250.24% |
| Variazione a 5 anni | 312.57% |
| Variazione dall'IPO | 9,029.85% |
Notizie e aggiornamenti recenti
Recent updates
Aggiornamento narrativa • Sep 09
TEVA: Celiac And Vitiligo Data Are Expected To Drive Neuroscience Pivot
Analysts have lifted their fair value estimate for Teva Pharmaceutical Industries to $41.91 from $40.90, citing stronger assumed revenue growth, a slightly higher future P/E multiple, and recent Street research that highlights commercial execution and a maturing pipeline in areas such as celiac disease and Tourette's syndrome. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries focuses on how the company is executing on its growth plans and how that might support current valuation levels.Seeking Alpha • Aug 03
Teva's Re-Rating Still Has Room To Run
Summary Teva Pharmaceutical is undergoing a transformation, shifting its revenue mix toward specialty and innovative drugs, now over $1 billion per quarter. TEVA targets $3.7 billion in specialty/innovative sales for 2026 and aims for operating margins near 30% by 2027, driven by product mix and cost savings. Leverage has dropped below 3x EBITDA, with a goal of 2x by 2027, supported by $2–$2.4 billion free cash flow guidance for 2026. I maintain a Buy rating, as TEVA still trades below sector multiples and further upside is possible if specialty growth and margin targets are met. Read the full article on Seeking Alpha
Aggiornamento narrativa • Jul 21
TEVA: Fairly Valued Outlook Will Weigh Vitiligo Data And Biosimilar Expansion
Analysts have lifted their fair value estimate for Teva Pharmaceutical Industries from about $21.53 to roughly $33.08, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E multiples, along with recent price target increases across several firms and renewed confidence in the vitiligo program despite short term share price weakness. Analyst Commentary Recent commentary on Teva Pharmaceutical Industries has centered on how investors should think about valuation relative to execution risk, particularly around the vitiligo program and the timing of clinical milestones.
Aggiornamento narrativa • Jul 07
TEVA: Vitiligo Readout And Neuroscience Expansion Are Expected To Drive Upside
Analysts have raised their fair value estimate for Teva Pharmaceutical Industries from $45.00 to about $48.72, citing updated assumptions around revenue growth, profit margins, and future P/E. These changes align with a series of recent price target increases across the Street.Aggiornamento narrativa • Jun 23
TEVA: Neuroscience Pivot And Vitiligo Readout Timing May Support 2026 Repricing
Teva Pharmaceutical Industries' analyst price target has been adjusted slightly to $40.90, with analysts pointing to recent stock underperformance tied to macro factors and updated vitiligo trial timelines, while maintaining underlying confidence in the pipeline and business fundamentals. Analyst Commentary Recent commentary on Teva Pharmaceutical Industries highlights a mix of optimism about the company’s pipeline execution and caution around near term headlines and timing.Articolo di analisi • Jun 21
Teva Pharmaceutical Industries (TEVA) Stock Could Be 23.7% Undervalued After Recent Pullback
Teva Pharmaceutical Industries (NYSE:TEVA) is back in focus after a recent share price pullback, with the stock closing at $31.48. Investors are assessing how the current valuation lines up with the company’s fundamentals. See our latest analysis for Teva Pharmaceutical Industries. The recent 7 day share price return, down 9.1%, and 1 month share price return, down 7.6%, contrast with a 1 year total shareholder return of 85.7% and 3 year total shareholder return above 3x. This suggests that...Aggiornamento narrativa • Jun 08
TEVA: Neuroscience Pipeline And Branded Shift May Support 2026 Multiple Reappraisal
Teva Pharmaceutical Industries' analyst price target has been adjusted from $40.27 to $41.27, as analysts factor in updated assumptions for revenue growth, profit margins and future P/E, supported by a series of recent price target increases from major research firms. Analyst Commentary Recent price target revisions for Teva Pharmaceutical Industries cluster tightly in favor of higher valuations, with several large firms, including JPMorgan, lifting their targets by between US$1 and US$6.Aggiornamento narrativa • May 25
TEVA: Focused R&D In Neuroscience And Immunology Will Support 2026 Multiple Reappraisal
Analyst price targets on Teva Pharmaceutical Industries have edged higher, with the updated fair value estimate moving from about $40.09 to $40.27 as analysts factor in recent target increases and their views on the company’s R&D focus, core therapeutic areas, biosimilars business, and capital deployment plans. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries points to a cluster of higher price targets, with several bullish analysts updating their models after discussions with management about research priorities, therapeutic focus, biosimilars, and capital deployment.Aggiornamento narrativa • May 04
TEVA: Neuroscience And Immunology Pipeline Will Drive 2026 Multiple Reappraisal
Analysts lifted the Teva Pharmaceutical Industries price target to $40.09 from $38.18, citing updated assumptions that point to higher revenue growth expectations, a slightly lower projected profit margin, and a higher future P/E multiple. This view is supported by recent research notes highlighting management's R&D focus, build out in core therapeutic areas, biosimilars vision, and capital deployment plans.Aggiornamento narrativa • Apr 16
TEVA: Neuroscience And Immunology R&D And Biosimilars Will Shape 2026 Reappraisal
Analysts have nudged their Teva Pharmaceutical Industries price targets higher, with the model fair value moving from $37.82 to $38.18. This change is supported by updated views on the company's R&D focus in neuroscience and immunology, its biosimilars plans, capital deployment, and the evolving outlook for partnered assets such as duvakitug.Nuova narrativa • Apr 09
Late Stage Pipeline And Margin Expansion Will Transform This Pharma Into A Future Cash Engine
Catalysts About Teva Pharmaceutical Industries Teva Pharmaceutical Industries develops and sells generic medicines, biosimilars and branded therapies across central nervous system, respiratory and immunology related diseases. What are the underlying business or industry changes driving this perspective?Aggiornamento narrativa • Apr 02
TEVA: Neuroscience And Immunology Pipeline Progress Will Shape 2026 R&D Reappraisal
Narrative Update on Teva Pharmaceutical Industries The analyst price target framework for Teva Pharmaceutical Industries has shifted modestly higher, with recent Street targets moving into the mid to high $30s and low $40s as analysts cite progress in R&D across neuroscience, immunology and biosimilars, improved capital structure and clearer long term EBITDA growth visibility. This comes even as the updated fair value estimate edges from $38.14 to $37.82 on slightly lower modeled revenue growth and profit margins, along with a marginally higher future P/E assumption.Aggiornamento narrativa • Mar 18
TEVA: 2026 Neuroscience And Immunology Pipeline Progress Will Drive Bullish Outlook
Teva Pharmaceutical Industries' analyst price target is modestly higher, with recent $1 to $9 upward revisions tied to analysts' expectations for R&D progress in neuroscience and immunology, a growing biosimilars presence, and stronger cash generation that supports a slightly richer forward P/E multiple. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries focus on how the pipeline, cash generation, and balance sheet shape both upside potential and execution risks.Aggiornamento narrativa • Mar 04
TEVA: Affordable Medicines And 2026 Pipeline Catalysts Will Drive Bullish Outlook
Analysts have nudged their price target for Teva Pharmaceutical Industries up to $38 from $37, reflecting a slightly higher fair value estimate and updated assumptions around long term revenue growth, margins, and the potential for duvakitug to reach $3b in peak sales following recent Phase 2 data with Sanofi. Analyst Commentary Recent research updates on Teva Pharmaceutical Industries highlight a mix of enthusiasm around the pipeline and affordability theme, alongside caution around execution risk and legal overhangs.Aggiornamento narrativa • Feb 18
TEVA: Affordable Medicines And 2026 R&D Progress Will Shape Medium Term Outlook
Narrative Update Overview The analyst price target for Teva Pharmaceutical Industries has been revised modestly higher to $37.95, with analysts pointing to updated fair value estimates, slightly adjusted discount rates, a new revenue growth outlook, and recent Street research highlighting potential pipeline catalysts and the appeal of affordable medicines heading into 2026. Analyst Commentary Recent Street research on Teva Pharmaceutical Industries has centered on refreshed price targets, the potential of the R&D pipeline heading into 2026, and the appeal of the affordable medicines theme.Aggiornamento narrativa • Feb 04
TEVA: Affordable Medicines And 2026 Pipeline Milestones Will Shape Medium Term Outlook
Analysts have raised their price targets on Teva Pharmaceutical Industries into a tighter valuation range, with our fair value estimate moving from US$35.32 to US$36.77. They point to improving profit margin assumptions, a lower future P/E, and support from recent research highlighting the affordable medicines theme and potential pipeline catalysts into 2026.Aggiornamento narrativa • Jan 20
TEVA: Affordable Medicines And 2026 Pipeline Catalysts Should Support Re Rating
Narrative Update Analysts have lifted their price target range for Teva Pharmaceutical Industries toward the mid US$30s, reflecting updated assumptions on fair value, profit margins, and future P/E as they point to affordable medicines and potential R&D catalysts around 2026 as key drivers of sentiment. Analyst Commentary Recent street research points to a more constructive tone around Teva Pharmaceutical Industries, with higher price targets tied to its focus on affordable medicines and potential R&D catalysts around 2026.Aggiornamento narrativa • Jan 06
TEVA: Shares Will Hold Steady As Q3 Trends Support Balanced Outlook
Analysts have nudged their price target for Teva Pharmaceutical Industries higher to about US$24, citing recent Q3 pricing and volume trends for key drugs and consistent expectations for earnings across commercial-stage biopharma names. Analyst Commentary Bullish Takeaways Bullish analysts view the higher US$24 price target as a reflection of steadier execution on key drugs, with recent Q3 pricing and volume trends supporting their valuation framework.Aggiornamento narrativa • Dec 22
TEVA: Shares Will Trade Sideways As IRA Pricing Clarity Drives Relief Rally
Analysts have raised their fair value estimate for Teva Pharmaceutical Industries to approximately $32.77 from about $28.61, citing recent price target increases to the mid 20 dollar range, expectations for stable Q3 performance, and a potential relief rally tied to upcoming Austedo IRA pricing clarity. Analyst Commentary Recent Street research reflects a generally constructive stance on Teva, with price targets moving higher in anticipation of stable near term execution and clearer visibility on Austedo economics under the Inflation Reduction Act.Aggiornamento narrativa • Dec 08
TEVA: Shares Will Trade Sideways As Drug Pricing Clarity Supports Margins
Analysts have nudged their average price target for Teva Pharmaceutical Industries higher from approximately $27.90 to about $28.60, citing stable near term earnings expectations, improving profit margin assumptions, and a potential relief rally tied to clarity on Austedo pricing under the IRA framework. Analyst Commentary Bullish analysts highlight that recent price target increases reflect growing confidence in Teva's ability to execute on its turnaround strategy and sustain earnings stability, even as broader biopharma peers face mixed revisions.Aggiornamento narrativa • Nov 24
TEVA: Shares Will Rally As IRA Drug Pricing Clarity Approaches
Teva Pharmaceutical Industries' analyst price target has been raised modestly, with analysts citing improved key drug performance and potential relief as regulatory pricing clarity emerges. This reflects a shift from approximately $27.45 to $27.90 per share.Articolo di analisi • Nov 13
We Think Teva Pharmaceutical Industries' (NYSE:TEVA) Healthy Earnings Might Be Conservative
Shareholders appeared to be happy with Teva Pharmaceutical Industries Limited's ( NYSE:TEVA ) solid earnings report...Articolo di analisi • Nov 12
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 26% Though Its Price And Business Still Lag The Industry
Despite an already strong run, Teva Pharmaceutical Industries Limited ( NYSE:TEVA ) shares have been powering on, with...Aggiornamento narrativa • Nov 07
TEVA: Stock Will Gain Momentum As Key Drug Pricing Decision Nears
Analysts have increased their price target for Teva Pharmaceutical Industries by approximately $3, citing improved Q3 trends as well as positive expectations for key drug pricing and regulatory developments. Analyst Commentary Recent updates from Street research highlight both optimistic outlooks and ongoing risks for Teva Pharmaceutical Industries as analysts revise their expectations following Q3 performance and future drug pricing developments.Aggiornamento narrativa • Oct 23
Analyst Commentary Highlights Modest Price Target Increase and Positive Outlook for Teva Pharmaceutical Industries
Teva Pharmaceutical Industries' analyst price target has increased modestly, rising by $0.22 to approximately $24.44 per share. Analysts cite improved pricing and volume trends, along with positive expectations for key drugs and limited Q3 surprises.Aggiornamento narrativa • Oct 09
Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand
Teva Pharmaceutical Industries saw its analyst price target increase modestly from $23.89 to $24.22 per share. Analysts cite anticipated relief rallies and favorable prospects for the company's Austedo pricing strategy.Aggiornamento narrativa • Sep 25
Aging Demographics And Biosimilar Launches Will Transform Healthcare Demand
As Teva Pharmaceutical Industries’ future P/E and revenue growth forecasts remain essentially unchanged, the consensus analyst price target is also largely flat, with a slight increase from $23.56 to $23.89. What's in the News UZEDY, Teva's long-acting injectable risperidone for schizophrenia, secured South Korean regulatory approval and has reached strong commercial milestones, recording $117 million in 2024 net sales and $95 million in the first half of 2025.
Nuova narrativa • Apr 23
Generics And Biosimilars Pipeline And Expansion Will Define Progress
The Pivot to Growth strategy targets revenue enhancement through product innovation, operational efficiency, and a sustainable generics business.Rendimenti per gli azionisti
| TEVA | US Pharmaceuticals | US Mercato | |
|---|---|---|---|
| 7D | 2.0% | -3.4% | -1.0% |
| 1Y | 86.1% | 44.7% | 14.1% |
Ritorno vs Industria: TEVA ha superato il US Pharmaceuticals che ha restituito 44.7 % nell'ultimo anno.
Rendimento vs Mercato: TEVA ha superato il mercato US che ha restituito 14.1 % nell'ultimo anno.
Volatilità dei prezzi
| TEVA volatility | |
|---|---|
| TEVA Average Weekly Movement | 5.1% |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Prezzo delle azioni stabile: TEVA non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di TEVA è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1901 | 32,008 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited sviluppa, produce, commercializza e distribuisce farmaci generici e di altro tipo, nonché prodotti biofarmaceutici negli Stati Uniti, in Europa, in Israele e a livello internazionale. Offre medicinali generici in varie forme di dosaggio, quali compresse, capsule, prodotti iniettabili, per inalazione, liquidi, cerotti transdermici, unguenti e creme; prodotti sterili, ormoni, farmaci ad alta potenza e sostanze citotossiche in forme di dosaggio parenterali e solide; e prodotti generici con dispositivi medici e prodotti combinati. L'azienda si concentra inoltre sul sistema nervoso centrale (SNC), sull'apparato respiratorio, sull'oncologia e su altre aree.
Teva Pharmaceutical Industries Limited Riepilogo dei fondamenti
| TEVA statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$42.36b |
| Utili (TTM) | US$706.00m |
| Ricavi(TTM) | US$17.32b |
61.2x
Rapporto P/E2.5x
Rapporto P/STEVA è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| TEVA Conto economico (TTM) | |
|---|---|
| Ricavi | US$17.32b |
| Costo del fatturato | US$8.23b |
| Profitto lordo | US$9.08b |
| Altre spese | US$8.38b |
| Utili | US$706.00m |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 0.61 |
| Margine lordo | 52.46% |
| Margine di profitto netto | 4.08% |
| Rapporto debito/patrimonio netto | 214.2% |
Come si è comportato TEVA nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/09/11 04:31 |
| Prezzo dell'azione a fine giornata | 2026/09/11 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Teva Pharmaceutical Industries Limited è coperta da 44 analisti. 11 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Balaji Prasad | Barclays |
| Glen Santangelo | Barclays |